シロスタゾールによる末梢血管インターベンションの十分な治療

基本情報

NCT ID

NCT00912756

ステータス

不明

試験のフェーズ

第4相

試験タイプ

介入

目標被験者数

200

治験依頼者名

Kansai Rosai Hospital

概要

Recently, Nanto et al. reported that cilostazol effectively prevented restenosis in a retrospective analysis of 121 femoropopliteal artery lesions in percutaneous transluminal angioplasty (PTA) patients who had undergone PTA. In a prospective 3-year follow-up study in 127 patients with similar diseases, the patency rate was significantly higher in the cilostazol group than in the ticlopidine group. It was also found that cilostazol markedly inhibited restenosis during the first 1-year period following endovascular therapy when restenosis is most frequently observed. In addition, there have been sporadic reports that cilostazol was effective in preventing post-stenting restenosis in the coronary artery area. Based on these results, this multicenter study is going to be conducted to prospectively evaluate the usefulness of cilostazol in lower limb endovascular therapy.

対象疾患

介入

依頼者（Sponsor）

実施施設 (13)